Get the Stockscreener App
9.00
0.11%
-0.010
After Hours:
9.18
0.18
+2.00%
Embecta Corp stock is traded at $9.00, with a volume of 766.61K.
It is down -0.11% in the last 24 hours and down -12.79% over the past month.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
See More
Previous Close:
$9.01
Open:
$9.11
24h Volume:
766.61K
Relative Volume:
0.99
Market Cap:
$532.98M
Revenue:
$1.08B
Net Income/Loss:
$139.50M
P/E Ratio:
3.7951
EPS:
2.3715
Net Cash Flow:
$205.80M
1W Performance:
+1.58%
1M Performance:
-12.79%
6M Performance:
-34.26%
1Y Performance:
-28.85%
1-Day Range:
$8.84
$9.175
1-Week Range:
$8.84
$9.465
52-Week Range:
$8.72
$15.55
Embecta Corp Stock (EMBC) Company Profile
Name
Embecta Corp
Sector
Industry
Phone
(862) 401-0000
Address
1209 ORANGE STREET, WILMINGTON
Compare EMBC vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EMBC
Embecta Corp
|
9.00 | 533.57M | 1.08B | 139.50M | 205.80M | 2.3715 |
ISRG
Intuitive Surgical Inc
|
469.98 | 167.61B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
158.27 | 44.35B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
75.26 | 36.19B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
42.67 | 34.11B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
226.31 | 33.24B | 5.40B | 1.49B | 1.78B | 10.12 |
Embecta Corp Stock (EMBC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Dec-02-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Nov-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-20-23 | Initiated | Wolfe Research | Peer Perform |
| Jan-06-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-08-22 | Initiated | BTIG Research | Neutral |
| Aug-01-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-22 | Initiated | BofA Securities | Underperform |
View All
Embecta Corp Stock (EMBC) Latest News
Understanding the Setup: (EMBC) and Scalable Risk - Stock Traders Daily
“Landmark moment” for medical device manufacturer with sale to Nasdaq-listed groupMills & Reeve advised - Insider Media Ltd
Embecta to Acquire Owen Mumford to Expand Drug-Delivery Portfolio - Yahoo Finance
Embecta agrees to acquire Owen Mumford - MSN
Embecta Plans Acquisition of Owen Mumford to Broaden Drug-Delivery Offerings - Bitget
Embecta to buy Owen Mumford for up to £150M - MSN
Performance Recap: Will Embecta Corp stock go up in YEAR2026 Earnings & Daily Volume Surge Signals - baoquankhu1.vn
Embecta: £150 Million Acquisition Of Owen Mumford To Expand Drug Delivery Platform Capabilities - Pulse 2.0
Embecta rallies after UK firm deal worth $200 million - MSN
Aug Gainers: What is the PEG ratio of Embecta Corp2026 Big Picture & AI Forecasted Stock Moves - baoquankhu1.vn
Embecta to Acquire Owen Mumford for Up to £150 Million, Expanding Drug-Delivery Device Portfolio and Global Medical Supplies Presence 123 - Minichart
Embecta to Acquire Owen Mumford in £150M Deal, Expanding Drug Delivery and Chronic Care Portfolio - Pharmacy Times
Embecta to Acquire Owen Mumford, Expanding Drug-Delivery Portfolio - TipRanks
Embecta (NASDAQ: EMBC) to acquire Owen Mumford in up to £150m deal - Stock Titan
Embecta to acquire Owen Mumford for up to £150 million By Investing.com - Investing.com India
Embecta Corp. agreed to acquire Owen Mumford Holdings Limited from Mark Owen, Adam Mumford, Ellen Owen, Kim Priddis,Nancy Millington and others for approximately £150 million. - marketscreener.com
EmbectaAn Interesting Deal At An Interesting Time (NASDAQ:EMBC) - Seeking Alpha
Embecta to buy auto-injector maker Owen Mumford for $200M to diversify beyond insulin - Fierce Biotech
Embecta to acquire auto-injector maker Owen Mumford for up to $199.4M - Drug Delivery Business
Embecta to buy Owen Mumford for up to $201M - MedTech Dive
Embecta to acquire UK medical device maker Owen Mumford for $200M - NJBIZ
Embecta (NASDAQ:EMBC) Trading 4.5% HigherTime to Buy? - MarketBeat
Embecta to Acquire Owen Mumford for up to $199.4M - Medical Product Outsourcing
Embecta acquires Owen Mumford for £150M - BioWorld MedTech
Embecta’s $133M Acquisition of Owen Mumford Marks a Turning Point - Medical Device and Diagnostic industry
Embecta Rallies After UK Firm Deal Worth $200 Million - Benzinga
BTIG reiterates Embecta stock Buy rating on Owen Mumford deal By Investing.com - Investing.com Australia
BTIG reiterates Embecta stock Buy rating on Owen Mumford deal - Investing.com UK
Embecta to acquire Owen Mumford - Drug Store News
Embecta Corp. Stock Plummets to New 52-Week Low of $8.74 - Markets Mojo
Embecta announces definitive agreement to acquire Owen Mumford Holdings Limited - marketscreener.com
Embecta to acquire Owen Mumford for up to £150 million - Investing.com
Embecta’s Purchase of Owen Mumford Establishes Q3 2026 as a Key Driver for Surpassing Earnings Expectations and Strategic Valuation Shift - Bitget
Embecta bets up to £150M to expand from diabetes care into drug delivery - Stock Titan
The recent acquisition projects undertaken by Embecta Corp are expected to inject new momentum into the company's revenue growth in fiscal year 2027 and gradually improve profitability in subsequent fiscal years. - Bitget
Embecta (NASDAQ:EMBC) Reaches New 1-Year LowShould You Sell? - MarketBeat
Embecta Corp. (NASDAQ:EMBC) Sees Large Increase in Short Interest - MarketBeat
BTIG Lowers PT on Embecta Corp. (EMBC) to $25, Keeps a Buy Rating - MSN
The Technical Signals Behind (EMBC) That Institutions Follow - Stock Traders Daily
Embecta Corp. Stock Plummets to New 52-Week Low of $9.06 - Markets Mojo
Embecta Corp. Stock Plummets to New 52-Week Low of $8.81 - Markets Mojo
Embecta (NASDAQ:EMBC) Hits New 1-Year LowHere's What Happened - MarketBeat
NanoTess lands Embecta deal to put its tech in 14,000 Canadian pharmacies - BetaKit
Embecta Stock Pre-Market (+6.5%): Enters Wound Care Market with Canadian Distribution Deal - Trefis
Calgary Startup NanoTess Signs Deal with Diabetes Care Leader embecta to Bring Catalytic Wound Care to All Canadians - Yahoo Finance
Jefferies Financial Group Inc. Boosts Stock Position in Embecta Corp. $EMBC - MarketBeat
Embecta (NASDAQ:EMBC) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Technical Analysis: Can Embecta Corp withstand a market correctionJuly 2025 Institutional & Weekly Top Gainers Trade List - baoquankhu1.vn
Embecta (NASDAQ:EMBC) Sets New 52-Week LowHere's What Happened - MarketBeat
Embecta Corp Stock (EMBC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):